Last reviewed · How we verify

PharmaKing — Portfolio Competitive Intelligence Brief

PharmaKing pipeline: 1 marketed, 0 filed, 3 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 4 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
PENNEL PENNEL marketed Other
NISSEL NISSEL phase 3
Oltipraz 2 (120mg) Oltipraz 2 (120mg) phase 3 Phase II enzyme inducer / chemopreventive agent NAD(P)H quinone oxidoreductase (NQO1), glutathione S-transferases (GSTs) Oncology / Chemoprevention
Oltipraz 1 (90mg) Oltipraz 1 (90mg) phase 3 Phase II enzyme inducer NQO1, GST, Nrf2 pathway Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for PharmaKing:

Cite this brief

Drug Landscape (2026). PharmaKing — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pharmaking. Accessed 2026-05-13.

Related